Royal Sense Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹37(54.41%)
Premium (ELP)
Royal Sense Limited's successfully completed its Initial Public Offering and commenced trading on Mar 19, 2024 at the BSE exchange. The company raised 14,50,000 Shares through this public offering, comprising 14,50,000 Shares in fresh capital.
The IPO was priced within the band of ₹68 to ₹68, with minimum application lots of 2000 shares. The offering attracted significant investor interest during its subscription period from Mar 12, 2024 to Mar 14, 2024.
Share allotment was finalized on Mar 15, 2024, distributing equity to successful applicants. The stock's subsequent listing marked a significant milestone in the company's corporate history, providing public market liquidity to shareholders.
Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.
Royal Sense Limited, established in 2023, is a dedicated provider of medical equipment, surgical instruments, consumables, laboratory essentials, and diagnostic kits. Originally operating under the proprietorship of Mr. Rishabh Arora as "M/s Royal Traders, PHT and Anaya," the company transitioned into its current structure following its acquisition on April 28, 2023. Catering to the Ministry of Health Departments in Uttar Pradesh, Himachal Pradesh, Rajasthan, and Jammu & Kashmir, as well as government institutions and private hospitals across India, Royal Sense Limited ensures the reliable supply of essential healthcare products. With a dedicated team of 8 professionals as of June 30, 2023, the company remains committed to delivering high-quality medical solutions nationwide.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
- Expanding Digital Capabilities: Leveraging e-commerce and digital platforms for direct B2B and B2C sales, reducing dependency on traditional procurement models.
- Product Innovation & R&D: Investing in research and partnerships to develop high-demand, high-margin healthcare products, such as telemedicine solutions or AI-driven diagnostics.
- Regulatory & Compliance Strengthening: Ensuring robust compliance with healthcare regulations to maintain trust and eligibility for institutional contracts.
- Strategic Market Expansion: Exploring untapped markets, both geographically and through product diversification, to reduce dependence on existing customer segments.
- Supplier Diversification & Inventory Buffer: Establishing relationships with multiple suppliers and maintaining a strategic inventory reserve to minimize supply chain disruptions.
- Government & Institutional Partnerships: Strengthening ties with healthcare institutions and government agencies to secure long-term contracts and reduce reliance on volatile customer orders.
- Robust Financial & Credit Risk Management: Implementing strict credit control policies and diversifying revenue streams to manage uncertain customer payments.
- Regulatory Compliance & Legal Readiness: Investing in a strong regulatory affairs team to ensure timely approvals and proactive compliance with evolving industry regulations.
- Building Market Credibility: Leveraging case studies, partnerships, and financial transparency to mitigate concerns about its limited operating history and attract investor confidence.
- Mr. Rishabh Arora
Royal Sense Limited
Bigshare Services Private Limited